Meeting Report

Recent Advances in the Treatment Of Newly Diagnosed Multiple Myeloma

Presented by Edward Libby,(1) MD, and Josh Epworth,(2) ARNP

From (1)University of Washington and Washington University Medical Center, Seattle, Washington; (2)Seattle Cancer Care Alliance, Seattle, Washington

Presenters’ disclosures of conflicts of interest are found at the end of this article.


J Adv Pract Oncol 2020;11(3):301–305 | https://doi.org/10.6004/jadpro.2020.11.3.17 | © 2020 Harborside™


  

ABSTRACT

Edward Libby, MD, and Josh Epworth, ARNP, interpreted data on current and novel treatments, discussed how to select initial therapy based on patient risk and in alignment with guidelines and best practices, and evaluated the use of minimal residual disease testing in patients with multiple myeloma. 




For access to the full length article, please sign in.

Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
ADVERTISEMENT
Section Seperator
Copyright © 2010-2019 Harborside Press, LLC All rights reserved.               
Home | Current Issue | Previous Issue | Submissions | About JADPRO | Advertising | Privacy Policy | Contact | Copyright Notice/Disclaimer | Subscribe
Bot trap - Don't go here
By continuing to browse this site you permit us and our partners to place identification cookies on your browser and agree to our use of cookies to identify you for marketing. Read our Privacy Policy to learn more.